Replies to post #59057 on Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Ariad's Harvey Berger has tried every imaginable way to boost the share price of Ariad over the last 6 months, and no one, and I mean no one believes in him as the share price clearly shows. There are a ton of new biotechs coming public now, with much brighter futures, with less toxic concerns. It will be extremely difficult for Ariad to capture investor money now with all the competition in the biotech space. I have seen this road before in the tech space.

[biotech_researcher]

http://stafforddaily.com/credit-suisse-rating-disclosure-on-ariad-pharmaceuticals-inc-2/327900

Equity analysts at the Brokerage firm Credit Suisse downgrades its rating on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). The rating major has initiated the coverage with an underperform rating on the shares. Earlier, the shares were rated a Neutral by the brokerage firm. The Analysts at Credit Suisse lowers the price target from $8 per share to $6 per share. Many firms have commented on the short term and long term price target. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA): 12 Analyst have given the stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) a near short term price target of $9.04. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $2.78. The higher price target estimate is at $14 while the lower price estimates are fixed at $5.

[wilco244]

I respectfully disagree. He has had over 20 years to get it right and it is time for a new approach. New eyes, new ideas can do no worse than what we have experienced under his leadership. JMHO